These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 38693853)
1. Prognostic and immunotherapeutic implications of bilirubin metabolism-associated genes in lung adenocarcinoma. Ren K; Ling X; Chen L; Li Z; Huang T J Cell Mol Med; 2024 May; 28(9):e18346. PubMed ID: 38693853 [TBL] [Abstract][Full Text] [Related]
2. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma. Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q Front Immunol; 2021; 12():693062. PubMed ID: 34497605 [TBL] [Abstract][Full Text] [Related]
3. The Comprehensive Analysis Identified an Autophagy Signature for the Prognosis and the Immunotherapy Efficiency Prediction in Lung Adenocarcinoma. Li X; Dai Z; Wu X; Zhang N; Zhang H; Wang Z; Zhang X; Liang X; Luo P; Zhang J; Liu Z; Zhou Y; Cheng Q; Chang R Front Immunol; 2022; 13():749241. PubMed ID: 35529878 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma. Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J Cancer Immunol Immunother; 2021 Dec; 70(12):3651-3667. PubMed ID: 33977344 [TBL] [Abstract][Full Text] [Related]
5. Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma. Bao X; Shi R; Zhao T; Wang Y J Mol Med (Berl); 2020 Jun; 98(6):805-818. PubMed ID: 32333046 [TBL] [Abstract][Full Text] [Related]
6. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma. Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J Front Immunol; 2023; 14():1217590. PubMed ID: 37492563 [TBL] [Abstract][Full Text] [Related]
7. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma. Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739 [TBL] [Abstract][Full Text] [Related]
8. A gene expression-based immune signature for lung adenocarcinoma prognosis. Wang L; Luo X; Cheng C; Amos CI; Cai G; Xiao F Cancer Immunol Immunother; 2020 Sep; 69(9):1881-1890. PubMed ID: 32372138 [TBL] [Abstract][Full Text] [Related]
9. Development of m6A/m5C/m1A regulated lncRNA signature for prognostic prediction, personalized immune intervention and drug selection in LUAD. Ma C; Gu Z; Yang Y J Cell Mol Med; 2024 Apr; 28(8):e18282. PubMed ID: 38647237 [TBL] [Abstract][Full Text] [Related]
10. Mast cell-based molecular subtypes and signature associated with clinical outcome in early-stage lung adenocarcinoma. Bao X; Shi R; Zhao T; Wang Y Mol Oncol; 2020 May; 14(5):917-932. PubMed ID: 32175651 [TBL] [Abstract][Full Text] [Related]
11. Genome‑wide investigation of the clinical significance and prospective molecular mechanisms of kinesin family member genes in patients with lung adenocarcinoma. Zhang L; Zhu G; Wang X; Liao X; Huang R; Huang C; Huang P; Zhang J; Wang P Oncol Rep; 2019 Sep; 42(3):1017-1034. PubMed ID: 31322267 [TBL] [Abstract][Full Text] [Related]
12. Immune landscape and a promising immune prognostic model associated with TP53 in early-stage lung adenocarcinoma. Wu C; Rao X; Lin W Cancer Med; 2021 Feb; 10(3):806-823. PubMed ID: 33314730 [TBL] [Abstract][Full Text] [Related]
13. Analyzing the characteristics of immune cell infiltration in lung adenocarcinoma via bioinformatics to predict the effect of immunotherapy. Liao Y; He D; Wen F Immunogenetics; 2021 Oct; 73(5):369-380. PubMed ID: 34302518 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Cell Death Index for Lung Adenocarcinoma: A Comprehensive Transcriptome-Based Analysis of Twelve Programmed Cell Death Pattern Genes. Chen F; Ma J; Hu S; Wu C; Chen S; Lin J Front Biosci (Landmark Ed); 2024 Apr; 29(4):135. PubMed ID: 38682187 [TBL] [Abstract][Full Text] [Related]
15. Identifying an immunogenic cell death-related gene signature contributes to predicting prognosis, immunotherapy efficacy, and tumor microenvironment of lung adenocarcinoma. Li X; Zhang D; Guo P; Ma S; Gao S; Li S; Yuan Y Aging (Albany NY); 2024 Apr; 16(7):6290-6313. PubMed ID: 38575204 [TBL] [Abstract][Full Text] [Related]
16. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on B cell marker genes to predict prognosis and immunotherapy response in lung adenocarcinoma. Song P; Li W; Wu X; Qian Z; Ying J; Gao S; He J Cancer Immunol Immunother; 2022 Oct; 71(10):2341-2354. PubMed ID: 35152302 [TBL] [Abstract][Full Text] [Related]
17. Prognostic value and immune infiltration of a novel stromal/immune score-related P2RY12 in lung adenocarcinoma microenvironment. Yu L; Cao S; Li J; Han B; Zhong H; Zhong R Int Immunopharmacol; 2021 Sep; 98():107734. PubMed ID: 34175738 [TBL] [Abstract][Full Text] [Related]
18. Deciphering the heterogeneity dominated by tumor-associated macrophages for survival prognostication and prediction of immunotherapy response in lung adenocarcinoma. Sun J; Guo H; Nie Y; Zhou S; Zeng Y; Sun Y Sci Rep; 2024 Apr; 14(1):9276. PubMed ID: 38653742 [TBL] [Abstract][Full Text] [Related]
19. Construction of the optimization prognostic model based on differentially expressed immune genes of lung adenocarcinoma. Zhai Y; Zhao B; Wang Y; Li L; Li J; Li X; Chang L; Chen Q; Liao Z BMC Cancer; 2021 Mar; 21(1):213. PubMed ID: 33648465 [TBL] [Abstract][Full Text] [Related]
20. A ferroptosis-related gene signature predicts overall survival in patients with lung adenocarcinoma. Gao X; Tang M; Tian S; Li J; Liu W Future Oncol; 2021 Apr; 17(12):1533-1544. PubMed ID: 33432837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]